On air · 2 of 3 networks
Evaluate Ltd
- evaluate.com
- Healthcare & Life Sciences
- GB
- 122 employees
Evaluate Ltd’s ads on LinkedIn, Meta and Google, recorded by adsrunning. Browse the latest here for free. Sign up free to see all 646. Watch Evaluate Ltd with Starter to get each new one in your feed.
Watchlist with Starter · $49/mo
| Network | Status | Live ads | Nov 2025LinkedIn activity · 52 weeksOct 2026 | Checked | Next step |
|---|---|---|---|---|---|
| Running | 24 | Checked 30 Oct 2026 | See all 646 ads → | ||
| Meta | Not checked | — | |||
| Running | 97 | Ads on the Google Ads Transparency Center | Checked 28 Oct 2026 | Collect them with the API → |
Evaluate Ltd has 24 live LinkedIn ads. We recorded 97 Google ads on 28 Oct 2026.
Latest ads
- LINKEDIN · IMAGESince 22 Oct 2026
AI may be everywhere in commercial pharma, but defensible answers are much harder to find. While most teams are testing general-purpose tools, these platforms often lack the curated data, pharmaceutical context and traceability needed to support decisions with real commercial consequences. Explore the infographic to see what separates AI built for demos from AI built for decisions.
- LINKEDIN · IMAGESince 22 Oct 2026
With rapid market growth, major patent expirations and innovative therapies reshaping the competitive landscape, the race for immunology leadership is on. In the latest episode of Evaluate Spotlight, discover which companies are positioned to lead through 2032, where dealmaking is heading and how precision approaches are opening new opportunities.
- LINKEDIN · IMAGESince 22 Oct 2026
After years of pharma exits, CNS is back in the spotlight. But what's driving renewed investment, and how are dealmakers navigating a market where clinical evidence matters more than ever? In Episode 2 of our Spotlight series, Evaluate experts Wen-Yu Huang and Emma Wille explore the latest CNS M&A and licensing trends, shifting investment priorities and emerging technologies attracting capital.
- LINKEDIN · IMAGESince 22 Oct 2026
Most commercial teams are experimenting with AI, yet only 9% of pharma leaders say it is truly transformational today. The gap is not simply about adoption: it is about whether the tools can deliver accurate, explainable outputs based on intelligence that is relevant to the decision at hand. Download the infographic to discover what the data reveals about the current state of AI in commercial pharma.
- LINKEDIN · SPOTLIGHTSince 12 Oct 2026
Power smarter pharma and biotech investment banking decisions
- LINKEDIN · SPOTLIGHTSince 12 Oct 2026
Access trusted intelligence across the pharma and biotech ecosystem
6 of 646 adsSign up to see every Evaluate Ltd ad, filter by format and date, and get alerts on new ones.
See all 646 adsWatch the companies you care about.
Filter every ad by industry, country, format and network, and get alerts when a company you watch starts running new ads.